Explore specialised treatment pathways combining conventional medicine, innovative therapies, intensive rehabilitation and selected Chinese treatment methods.
Not general medical travel, but a pre-assessed pathway for each condition with a defined indication, treatment options, evidence status and selection criteria.
An intensive recovery pathway for patients with persistent motor, speech, swallowing or functional limitations after stroke. The emphasis is on measurable neurorehabilitation, with specialised Chinese treatment methods used only as an adjunct to conventional rehabilitation.
Evidence status: Evidence-informed adjunctive care
For patients with moderate to severe psoriasis, China may be of interest because of the combination of modern dermatology, newer locally available biologics, phototherapy and specialised dermatological TCM techniques.
Evidence status: Strong conventional options + meaningful integrative adjunct
For persistent neuropathic pain, an intensive combined programme may be relevant when medication, conventional pain care and rehabilitation have produced insufficient results. In China, conventional pain techniques are often combined with specialised forms of acupuncture and daily rehabilitation.
Evidence status: Selected indications; integrated approach
For patients who receive insufficient treatment intensity in Europe, a temporary daily rehabilitation programme with physiotherapy, occupational therapy, speech therapy and specialist supervision may offer a practical advantage.
Evidence status: Conventional evidence-based care
A complete medical reassessment for people over 60 who are experiencing physical decline, have multiple diagnoses or medications, and want their health reviewed comprehensively. Not a wellness concept, but geriatrics, internal medicine, pharmacology and lifestyle in one pathway.
Evidence status: Strong foundation in geriatrics and medication optimisation
Early cognitive decline deserves a broader analysis than simply asking whether someone has Alzheimer’s disease. Vascular damage, sleep, medication, blood pressure, metabolic factors and neurodegeneration may all contribute.
Evidence status: Conventional diagnostics + China-specific treatment options
Medication remains the foundation of Parkinson’s treatment, but some patients continue to experience freezing, balance problems, stiffness, fluctuations or reduced mobility. China is investigating specialised needling techniques and intensive movement programmes as adjunctive approaches.
Evidence status: Adjunct to conventional neurological treatment
For parents who deliberately want to explore a non-stimulant route first, China may be of interest because of the combination of child psychiatric assessment, behavioural therapy and standardised Chinese medicinal products such as Jingling Oral Liquid.
Evidence status: Promising, but not a proven replacement for standard medication
China is rapidly developing new cellular therapies, targeted medicines and advanced radiotherapy techniques. For selected patients, this may provide access to treatment that is not yet available in Europe, is difficult to access or is considerably more expensive.
Evidence status: Highly indication-dependent; from established to experimental
In cases of rupture, gel bleed, siliconoma, capsular problems, migration or complex symptoms after implants, a specialised reconstructive and diagnostic pathway may be required. The aim is to identify and treat anatomical damage, not to offer an unproven ‘silicone detox’.
Evidence status: Specialist surgery and diagnostics
China has extensive experience with high-intensity focused ultrasound in selected women with uterine fibroids and adenomyosis. It may be relevant for patients seeking a uterus-preserving, non-invasive treatment option.
Evidence status: Established technology for selected indications
For a small group of patients with extremely treatment-resistant OCD, depression or other severe psychiatric disorders, China is investigating advanced neuromodulation such as DBS and focused ultrasound. This is not a pathway for routine first-line psychiatric care.
Evidence status: Highly specialised / partly experimental
China has a rapidly expanding pipeline of cell and gene therapies. For some rare conditions, a patient may be able to access a regulated product or clinical trial that is not yet available in Europe or is difficult to access in practice.
Evidence status: Access to regulated or trial-based innovation
Tinnitus remains a major unresolved healthcare problem. China has specialised TCM schools for tinnitus and hearing disorders, but the current evidence is not yet strong enough to claim a proven unique treatment.
Evidence status: Research candidate; evidence still insufficientThe options described are not a guarantee of treatment. Availability and suitability depend on diagnosis, indication, evidence level, individual risks and assessment by the treating medical team. Experimental care is identified as such.
A treatment journey always begins with an assessment of the diagnosis, medical history, previous treatments, medication, risks and the specific treatment objective.